Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 April;54(2) > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 April;54(2):168-76

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

REVIEWS  NUCLEAR CARDIOLOGY AT THE EVE OF THE NEW DECADE


The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 April;54(2):168-76

language: English

Metabolic imaging in myocardial ischemia and heart failure

Knuuti J. 1, Tuunanen H. 2

1 Turku PET Centre, University of Turku, Turku, Finland;
2 Department of Medicine, Turku University Hospital, Turku, Finland


PDF  


Myocardial ischemia and heart failure are accompanied by well characterized changes in myocardial substrate metabolism. While the normal heart in the fasting state mostly relies on oxidation of fatty acids for energy production, acute myocardial ischaemia is accompanied by increased exogenous myocardial glucose uptake and suppressed utilization of fatty acids. This metabolic shift can be detected using metabolic imaging using labeled glucose and fatty acid analogs. Recently, also specific tracers for the detection of myocardial hypoxia have been tested. In the assessment of myocardial viability metabolic imaging has an established role. Metabolic imaging has also greatly improved our understanding about metabolic derangements in the failing heart and currently metabolic modulation as a therapy of heart failure is studied. While experimental and clinical results are promising, larger clinical trials are warranted to better understand the value of metabolic imaging in the detection and prognosis of ischemic heart disease.

top of page

Publication History

Cite this article as

Corresponding author e-mail

uhani.knuuti@utu.fi